POSTER: AML-111 Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)

Ibrahim Aldoss; Ghayas C. Issa; James S. Blachly; Michael J. Thirman; Gabriel N. Mannis; Martha L. Arellano; John F. DiPersio; Elie Traer; C. Michel Zwaan; Neerav Shukla; Branko Cuglievan; Carolyn S. Grove; Matthew Greenwood; Christine M. McMahon; Alexander E. Perl; Richard M. Stone; Cristina Papayannidis; David S. Dickens; Maël Heiblig; Andrius Žučenka; Pau Montesinos; Ioannis Mantzaris; Tibor Kovacsovics; Paul J. Shami; Li Yu; Rebecca G. Bagley; Angela R. Smith; Eytan M. Stein

doi:10.1016/S2152-2650(25)00489-6

$POSTER: AML-111 Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)$

Abstract

Peer reviewed

POSTER: AML-111 Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)

Ibrahim Aldoss, Ghayas C. Issa, James S. Blachly, Michael J. Thirman, Gabriel N. Mannis, Martha L. Arellano, John F. DiPersio, Elie Traer, C. Michel Zwaan, Neerav Shukla, …

Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S181-S181

09/2025

DOI: 10.1016/S2152-2650(25)00489-6

View Online

Details

Title: Subtitle: POSTER: AML-111 Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)
Creators: Ibrahim Aldoss - City Of Hope National Medical Center
Ghayas C. Issa - The University of Texas MD Anderson Cancer Center
James S. Blachly - The Ohio State University
Michael J. Thirman - University of Chicago
Gabriel N. Mannis - Stanford University School of Medicine
Martha L. Arellano - Winship Cancer Institute
John F. DiPersio - Washington University in St. Louis School of Medicine
Elie Traer - OHSU Knight Cancer Institute
C. Michel Zwaan - Princess Máxima Center
Neerav Shukla - Memorial Sloan Kettering Cancer Center
Branko Cuglievan - The University of Texas MD Anderson Cancer Center
Carolyn S. Grove - Sir Charles Gairdner Hospital
Matthew Greenwood - The University of Sydney
Christine M. McMahon - University of Colorado School of Medicine, Aurora, CO, USA
Alexander E. Perl - University of Pennsylvania
Richard M. Stone - Dana-Farber Cancer Institute
Cristina Papayannidis - IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
David S. Dickens - University of Iowa
Maël Heiblig - Hôpital Lyon Sud
Andrius Žučenka - Vilnius University
Pau Montesinos - Hospital Universitari i Politècnic La Fe
Ioannis Mantzaris - Montefiore Einstein Comprehensive Cancer Center
Tibor Kovacsovics - City Of Hope National Medical Center
Paul J. Shami - University of Utah
Li Yu - Syndax Pharmaceuticals, Inc., New York, NY, USA
Rebecca G. Bagley - Syndax Pharmaceuticals, Inc., New York, NY, USA
Angela R. Smith - Syndax Pharmaceuticals, Inc., New York, NY, USA
Eytan M. Stein - Memorial Sloan Kettering Cancer Center
Resource Type: Abstract
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S181-S181
DOI: 10.1016/S2152-2650(25)00489-6
ISSN: 2152-2650
Publisher: Elsevier Inc
Language: English
Date published: 09/2025
Academic Unit: Stead Family Department of Pediatrics; Hematology/Oncology
Record Identifier: 9984949517302771

Metrics

4 Record Views